2023 World Conference on Lung Cancer (Posters)-EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study

EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

This retrospective study aimed to investigate the prognostic value of body mass index (BMI) and serum lipids in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immunotherapy. The study found that overweight patients had significantly prolonged survival compared to underweight and normal weight patients. The longest progression-free survival (PFS) was observed in overweight patients, although the difference was not statistically significant. Additionally, low levels of high-density lipoprotein cholesterol (HDL-C), liver metastasis, bone metastasis, other distant metastasis, and high lactate dehydrogenase (LDH) were associated with shorter PFS and overall survival (OS) in both univariable and multivariable analysis. Patients over 70 years of age had worse OS. Multivariable analysis showed that overweight was significantly associated with better PFS and OS, and low levels of low-density lipoprotein cholesterol (LDL-C) were associated with improved OS. High levels of small and low-density lipoprotein (sdLDL) and serum total cholesterol (TC) were positively related to PFS and OS. Adverse effects on PFS and OS were observed in patients with ECOG2 and low albuminemia, and squamous carcinoma had a negative impact on OS. The study highlights the potential prognostic value of BMI and serum lipid levels in predicting outcomes in NSCLC patients undergoing first-line immunotherapy. Further studies are warranted to verify these findings and explore the underlying mechanisms. Contact information for the corresponding author is provided on the document.

Asset Subtitle

Yanxin Sun

Meta Tag

Speaker Yanxin Sun

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

prognostic value

body mass index

BMI

serum lipids

non-small cell lung cancer

NSCLC

first-line immunotherapy

overweight patients

progression-free survival